Market Forecast
Registering
a CAGR of 5.4%, Anxiety Disorder Treatment Market Size is expected to reach USD 16.96 Million by 2025.
People
with anxiety disorders may feel anxious most of the time or for the brief,
intense episodes, which may occur for no apparent reason. The main categories
of anxiety disorders include phobia, panic disorder, generalized anxiety
disorder, social anxiety disorder, selective mutism, and separation anxiety
disorder.
Numerous
established players dominate the market. The key players are involved in
strategic initiatives to strengthen their market positions and expand their
geographic presence in developing regions. Many players are investing in
research activities to develop effective therapies to sustain in the market.
For instance, Eli Lilly and Company launched Duloxetine and Forest
Laboratories, Inc. launched Vilazodone, used for the treatment of generalized
anxiety disorder.
Market Influencers
Strategic
initiatives, mergers & acquisitions, partnerships, agreements, product
launches, government approvals, and expansion of manufacturing facilities by
major key players are positively influencing the market.
Regional Analysis
On a
regional basis, the Americas is anticipated to dominate the global Anxiety
Disorder Treatment Market Size owing to the rising incidence of anxiety
disorders in the region. For instance, generalized anxiety disorder affects 6.8
million adults, or 3.1% of the US population every year. Moreover, rising
awareness campaigns regarding the anxiety disorders by the government and
public organizations is driving the growth of the market in this region. For
instance, the Anxiety and Depression Association of America (ADAA) started an
initiative named BreaktheStigma. This campaign raises awareness regarding
mental illness and end stigma and creates hope for those affected by mental
illness.
Europe is
expected to hold the second-largest position in the global Anxiety Disorder
Treatment Market Size owing to supportive government policies and raising
public awareness about anxiety disorder treatments.
Asia-Pacific
is anticipated to be the fastest-growing region is due to the growing
prevalence of psychological conditions such as anxiety disorders, rising
interest of major key players in emerging markets, good quality healthcare
infrastructure in this region. The Middle East & Africa has the least share
of the global Anxiety Disorder Treatment Market Size. This is attributable to
limited healthcare infrastructure and a lack of awareness about anxiety
disorder treatments in this region.
Browse Full Report Details
@ https://www.marketresearchfuture.com/reports/anxiety-disorder-treatment-market-8455
Segmentation
The
Global Anxiety Disorder Treatment Market Size has been segmented into drug
class and end-user.
By drug
class, the market has been segmented into SSRIs (selective serotonin reuptake
inhibitors), SNRIs (serotonin-norepinephrine reuptake inhibitors), TCAs
(tricyclic antidepressants), pregabalin,
buspirone, benzodiazepines, and others.
The
global Anxiety Disorder Treatment Market Size, by end-user, has been segmented
into hospitals, mental healthcare centers, asylums, and others.
Key Players
- Bristol-Myers Squibb Company
(US)
- Eli Lilly and Company (US)
- Johnson & Johnson (US)
- AstraZeneca PLC (UK)
- Sanofi-Aventis (France)
- Forest Laboratories, Inc.
(US)
- Pfizer, Inc. (US)
- GlaxoSmithKline PLC (UK)
- Lundbeck A/S (Denmark)
- Merck & Co., Inc. (US)
No comments:
Post a Comment